Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 31,346 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study participants Clear all

Conditions: Obesity, Type 2 Diabetes
Interventions: Aspartame, Sucrose, Stevia; Dietary Supplement
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Overweight and Obesity, Endothelial Dysfunction, Cardiovascular Risk Factor
Interventions: Walnut Intake; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Davis, California

Conditions: Lung Carcinoma
Interventions: Liquid Biopsy, Low Dose Computed Tomography of the Chest, Survey Administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 50 Years to 80 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Healthy
Interventions: Calderasib OCT, Calderasib FCT; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Forehead Lines
Interventions: AGN-151586; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 5
States / cities: Newport Beach, California • New York, New York • Wilmington, North Carolina + 1 more

Conditions: Acute Myeloid Leukemia
Interventions: Brequinar/Brequinar + Ribavirin; Drug
Lead sponsor: Clear Creek Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 6
States / cities: Duarte, California • Boston, Massachusetts • Cleveland, Ohio + 1 more

Conditions: Cystic Fibrosis
Interventions: Investigator-designed lung transplant education resource (Research Intervention), Publicly available transplant education resource (Attention Control); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ischemia
Interventions: Communication with exercise therapist, mHealth-CR, Wearable activity monitoring device; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Cervical Cancer
Interventions: Zalifrelimab, Balstilimab; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 13
States / cities: Goodyear, Arizona • Duarte, California • Miami, Florida + 10 more

Conditions: Pancreatitis, Acute, Alcohol Drinking, Health Behavior
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Columbus, Ohio • Pittsburgh, Pennsylvania

Conditions: Depression, Stress, Sleep, Anxiety
Interventions: Moodlifters, Physical Activity, Nature Experiences; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 25 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Prediabetic State
Interventions: GlucoSupreme™ Herbal, Placebo; Dietary Supplement · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: Bradycardia, Heart Failure, Ventricular Dysfunction
Interventions: Ultra High Frequency Electrocardiogram (UHF-ECG); Device
Lead sponsor: VDI Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Avondale, Arizona • Mesa, Arizona • Chicago, Illinois + 4 more

Conditions: Glioma, Malignant, Surgery, Seizures
Interventions: Perampanel, Standard of Care; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Contraception
Interventions: Counseling; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteers
Interventions: Xanomeline/Trospium Chloride, Lithium, Valproic Acid, Lamotrigine; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Alamitos, California

Conditions: Non-Surgical Fat Reduction
Interventions: CoolSculpting Elite System; Device
Lead sponsor: AbbVie; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Vista, California

Conditions: Acute Migraine
Interventions: Elismetrep; Drug
Lead sponsor: TriGemX Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 113
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 93 more

Conditions: Primary Myelofibrosis
Interventions: LY5830966; Drug
Lead sponsor: Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 13
States / cities: Palo Alto, California • Tampa, Florida • Kansas City, Kansas + 8 more

Conditions: Traumas, Brain, Alzheimer Disease, Dementia, Head Injury, Concussion, Brain, TBI
Interventions: Combined Aerobic and Resistance Exercise + Caregiver Skills Training, Stretching Balance and Flexibility + Caregiver Skills Training; Behavioral
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 18 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Rheumatoid Arthritis
Interventions: JNJ-38518168, Placebo, Methotrexate; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Frederick, Maryland

Conditions: Myeloid Leukemia, Philadelphia Positive
Interventions: Asciminib Pediatric formulation group, Asciminib Adult formulation group; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 3
States / cities: Indianapolis, Indiana • Boston, Massachusetts • New York, New York

Conditions: Chronic Kidney Disease, Left Ventricular Hypertrophy
Interventions: paricalcitol, placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 30
States / cities: Phoenix, Arizona • Tempe, Arizona • San Diego, California + 24 more

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Efimosfermin Alfa, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 57
States / cities: Arcadia, California • Covina, California • Los Angeles, California + 44 more

Search by objective public record fields.

Effects of Stevia on Satiety and Eating Attitudes in Healthy, Overweight and Obese Adults

Influence of Walnut Intake on Vascular Function and Metabolism

Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer

A Study to Evaluate the Effect of Formulation and Food on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-011)

A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants

A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Lung Transplant READY Pilot Study

mHealth-CArdiac REhabilitation for INOCA

A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)

A Case-CrossovEr Study deSign to Inform Tailored Interventions to Prevent Disease Progression in Acute Pancreatitis

The Lived Experiences Measured Using Rings Pilot Study

RCT of a Polyherbal Dietary Supplement for Prediabetes

Ultra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED)

Effect of Perampanel on Peritumoral Hyperexcitability in HGG

Group Versus Individual Contraceptive Counseling for Resettled African Refugee Women

A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

The COACH Project: Combined Online Assistance for Caregiver Health

A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH